| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | -2,524 | -526 | 629 | 67 |
| Loss before income tax benefit (expense) | -1,573 | -1,777 | 956 | -2,373 |
| Income tax benefit (expense) | -4 | 7 | - | -8 |
| Net loss | -1,569 | -1,784 | 956 | -2,365 |
| Convertible and redeemable preferred stock deemed dividends | 111 | -1 | -3 | -5 |
| Net loss attributable to common stockholders | -1,680 | -1,785 | 953 | -2,370 |
| Net loss per share attributable to common stockholders- basic | -0.01 | -0.02 | 0.01 | -0.02 |
| Net loss per share attributable to common stockholders- diluted | -0.01 | -0.02 | 0 | -0.02 |
| Weighted-average shares used to compute net loss per share attributable to common shareholders - basic | 119,578,093 | 115,686,024 | 113,356,354 | 96,459,121 |
| Weighted-average shares used to compute net loss per share attributable to common shareholders - diluted | 119,578,093 | 115,686,024 | 6,039,898,041 | 96,459,121 |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)